epirubicin has been researched along with Inflammation in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (7.69) | 18.7374 |
| 1990's | 2 (15.38) | 18.2507 |
| 2000's | 6 (46.15) | 29.6817 |
| 2010's | 3 (23.08) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Bartsch, R; Deutschmann, C; Hacker, S; Haslik, W; Kornauth, C; Mader, RM; Nedomansky, J; Pluschnig, U; Steger, GG | 1 |
| Baltimore, D; Chora, A; Costa, P; Döring, G; Faridi, H; Ferreira, JA; Figueiredo, N; Gama-Carvalho, M; Gozzelino, R; Green, DR; Grompe, M; Gupta, V; Hartleben, B; Huber, TB; Marques, S; Martinez, J; Moita, C; Moita, LF; Neves-Costa, A; Pedroso, D; Pejanovic, N; Pereira, P; Pinto, A; Raquel, H; Simas, JP; Soares, MP; Zhang, Q; Zhao, JL | 1 |
| Cadeddu, C; Deidda, M; Dessì, M; Madeddu, C; Mantovani, G; Massa, E; Mercuro, G; Piras, A | 1 |
| Fritz, G; Grösch, S; Henninger, C; Huelsenbeck, J; Huelsenbeck, S; Kaina, B; Lackner, KJ; Schad, A | 1 |
| Capoccetti, F; Mezi, S; Modesti, M; Primi, F; Schillaci, O; Scopinaro, F | 1 |
| Bottomley, A; Coens, C; Cufer, T; de Haes, H; Dyczka, J; Efficace, F; Lichinitser, M; Piccart, MJ; Shepherd, L; Sprangers, MA; Therasse, P; van Steen, K; Welnicka-Jaskiewicz, M | 1 |
| Baldini, E; Collecchi, P; Evagelista, G; Gardin, G; Lionetto, R; Prochilo, T | 1 |
| Chevallier, B; Chollet, P; Clavere, P; Fargeot, P; Fumoleau, P; Kerbrat, P; Levy, C; Merrouche, Y; Roche, H; Veyret, C | 1 |
| Ando, M; Matsuyama, Y; Ooi, Y; Rai, Y; Sagara, Y; Takahama, T; Tamada, S; Tsuchimochi, S | 1 |
| Batel-Copel, L; Bernadou, A; Lauraine, EP; Malbec, L; Rodier, JM | 1 |
| Aieta, M; Cariello, A; Dazzi, C; Frassineti, GL; Giovanis, P; Marangolo, M; Molino, A; Rosti, G; Sabbatini, R; Tienghi, A; Vertogen, B | 1 |
| Gofuku, J; Katoh, T; Kawahara, T; Kobayakawa, K; Okamura, Y; Takatsuka, Y | 1 |
| Coombes, RC; Cunningham, D; Haydock, A; Hickish, T | 1 |
4 trial(s) available for epirubicin and Inflammation
| Article | Year |
|---|---|
Protective effects of the angiotensin II receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress, and early ventricular impairment.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antibiotics, Antineoplastic; Benzimidazoles; Benzoates; Cytokines; Echocardiography, Doppler; Epirubicin; Female; Heart; Humans; Inflammation; Inflammation Mediators; Male; Middle Aged; Myocardial Contraction; Oxidative Stress; Renin-Angiotensin System; Systole; Telmisartan; Ventricular Dysfunction, Left | 2010 |
Health-related quality of life parameters as prognostic factors in a nonmetastatic breast cancer population: an international multicenter study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Granulocyte Colony-Stimulating Factor; Health Status; Humans; Inflammation; Middle Aged; Predictive Value of Tests; Prognosis; Quality of Life | 2004 |
Inflammatory breast cancer outcome with epirubicin-based induction and maintenance chemotherapy: ten-year results from the French Adjuvant Study Group GETIS 02 Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Epirubicin; Female; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Inflammation; Lenograstim; Placebos; Recombinant Proteins; Remission Induction; Survival Rate | 2006 |
Neoadjuvant high dose chemotherapy plus peripheral blood progenitor cells in inflammatory breast cancer: a multicenter phase II pilot study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Inflammation; Leukapheresis; Middle Aged; Pilot Projects; Treatment Outcome | 2001 |
9 other study(ies) available for epirubicin and Inflammation
| Article | Year |
|---|---|
Tissue distribution of epirubicin after severe extravasation in humans.
Topics: Aged; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Agents; Cytokines; Doxorubicin; Epirubicin; Female; Humans; Inflammation; Male; Middle Aged; Necrosis; Skin Diseases; Surgical Flaps; Tissue Distribution; Wound Healing | 2021 |
Anthracyclines induce DNA damage response-mediated protection against severe sepsis.
Topics: Adenoviridae Infections; Animals; Anthracyclines; Anti-Bacterial Agents; Ataxia Telangiectasia Mutated Proteins; Autophagy-Related Protein 7; Cecum; DNA Damage; DNA Repair; Epirubicin; Fanconi Anemia Complementation Group D2 Protein; Inflammation; Inflammation Mediators; Injections, Intraperitoneal; Lung; Meropenem; Mice; Mice, Inbred C57BL; Microtubule-Associated Proteins; Organ Specificity; Peritonitis; Respiratory Tract Infections; Sepsis; Shock, Septic; Thienamycins; Whole-Body Irradiation | 2013 |
The lipid lowering drug lovastatin protects against doxorubicin-induced hepatotoxicity.
Topics: Animals; Antibiotics, Antineoplastic; Chemical and Drug Induced Liver Injury; Connective Tissue Growth Factor; DNA Damage; Dose-Response Relationship, Drug; Doxorubicin; Epirubicin; Gene Expression Regulation; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Liver Cirrhosis; Lovastatin; Mice; Mice, Inbred BALB C; Oxidative Stress; RNA, Messenger | 2012 |
In vivo detection of resistance to anthracycline based neoadjuvant chemotherapy in locally advanced and inflammatory breast cancer with technetium-99m sestamibi scintimammography.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Drug Resistance, Neoplasm; Epirubicin; Female; Humans; Inflammation; Middle Aged; Posture; Predictive Value of Tests; Radionuclide Imaging; Radiopharmaceuticals; Sensitivity and Specificity; Technetium Tc 99m Sestamibi | 2003 |
Long-term results of combined-modality therapy for inflammatory breast carcinoma.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Inflammation; Middle Aged; Neoplasm Staging; Prospective Studies; Randomized Controlled Trials as Topic; Survival Analysis; Tamoxifen; Time Factors; Treatment Outcome | 2004 |
[A case of inflammatory breast cancer achieving pathological complete response by primary systemic therapy with CEF (cyclophosphamide, epirubicin, 5-fluorouracil) followed by docetaxel].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Combined Modality Therapy; Cyclophosphamide; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Inflammation; Mammography; Middle Aged; Remission Induction; Taxoids; Tomography, X-Ray Computed; Ultrasonography, Mammary | 2007 |
Mediastinal infusion of epirubicin and 5-fluorouracil. A complication of totally implantable central venous systems. Report of a case.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Catheterization, Central Venous; Catheters, Indwelling; Epirubicin; Extravasation of Diagnostic and Therapeutic Materials; Fluorouracil; Humans; Inflammation; Infusions, Intravenous; Male; Mediastinum; Vena Cava, Superior | 1996 |
[A case of inflammatory breast cancer successfully treated with intra-arterial infusion of high-dose epirubicin].
Topics: Administration, Oral; Breast Neoplasms; Drug Administration Schedule; Epirubicin; Female; Humans; Inflammation; Infusions, Intra-Arterial; Middle Aged; Tamoxifen | 1991 |
Experience with intermediate-dose (110-120 mg/m2) epirubicin.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Dose-Response Relationship, Drug; Epirubicin; Female; Hematologic Diseases; Humans; Inflammation; Male; Middle Aged; Mucous Membrane; Nausea; Thrombophlebitis | 1989 |